Regulatory Review and Approval Sample Clauses

Regulatory Review and Approval. (a) Seller shall submit this agreement to the Commission for review and approval of the agreement under Section 1-75 of the Illinois Power Agency Act; and recovery by Buyer of the Contract Price payable by Buyer. Seller shall also submit to the Commission the formula rate (“Formula Rate”) that will use Seller’s Contract Price Components to determine the Monthly Contract Prices. The Parties acknowledge that for each Contract Year of this agreement, the Commission will determine the Contract Price Components and the Monthly Contract Price, based on the projections submitted by Seller and the Formula Rate. Exhibit 5.2(a) sets forth an example of the Formula Rate.
Sample 1
AutoNDA by SimpleDocs
Regulatory Review and Approval. Integra, through its authorized representatives, shall have completed a satisfactory review of the practices and procedures of the Company including, but not limited to, environmental and land use practices, import and export laws, compliance with contracts and federal, state and local laws and regulations governing the respective operations of the Company, which review reflects compliance with all applicable laws governing the Company, disclosing no material actual or probable violations, compliance problems, required capital expenditures or other substantive environmental, real estate and land use related concerns and which review is otherwise satisfactory in all respects to Integra, in its sole discretion.
Sample 1
Regulatory Review and Approval. FASTNET, through its authorized representatives, shall have completed a satisfactory review of the practices and procedures of the Company including, but not limited to, environmental and land use practices, import and export laws, compliance with contracts and federal, state and local laws and regulations governing the respective operations of the Company, which review reflects compliance with all applicable laws governing the Company, disclosing no material actual or probable violations, compliance problems, required capital expenditures or other substantive environmental, real estate and land use related concerns and which review is otherwise satisfactory in all respects to FASTNET, in its sole discretion.
Sample 1
Regulatory Review and Approval. (a) Seller shall submit this agreement to the Commission for review and approval of the agreement; and in the case of Electric Utility Buyers, full recovery by those Buyers of the Contract Price payable by Buyer from such customers, with such customers including, in the case of Electric Utilities, both Eligible Retail Customers and Non-Eligible Retail Customers. If required by the Commission, Seller shall also submit to the Commission (i) initial projections of its costs, revenues and credits (“Contract Price Components”) for the Term of this agreement; and (ii) the formula rate (“Formula Rate”) that will use Seller’s Contract Price Components to determine the Monthly Contract Prices. The Parties acknowledge that for each Contract Year of this agreement, the Commission will determine the Contract Price Components and the Monthly Contract Price, based on the projections submitted by Seller and the Formula Rate. Exhibit 5.2(a) sets forth an example of the Formula Rate. The Parties further acknowledge that the costs, revenues, and credits underlying the Contract Price Components may be subject to periodic audit and review for prudence and reasonableness, in a manner to be determined by the Commission.
Sample 1
Regulatory Review and Approval. (a) Seller shall submit this agreement to the Commission for review and approval of the agreement under Section 1-75 of the Illinois Power Agency Act; and full 43recovery by Buyer of the Contract Price payable by Buyer. 44 from its customers (for Electric Utilities, customers shall include Eligible Retail Customers and Non-Eligible Retail Customers). If required by the Commission, 45Seller shall also submit to the Commission46 the47: (i) initial projections of its costs, revenues and credits (“Contract Price Components”) for the Project for the term of this agreement; and (ii) a48 formula rate (“Formula Rate”) that will use Seller’s Contract Price Components to determine the Monthly Contract Prices. The Parties acknowledge that for each Contract Year of this agreement,49 the Commission will determine the50 Project51 Contract Price Components and the Monthly Contract Price, based on the projections submitted by Seller and the 52Formula53Fomula54 Rate. 55 Exhibit 5.2(a) sets forth an example of the Formula Rate.
Sample 1

Related to Regulatory Review and Approval

  • Review and Approval Documents specified above must be submitted for review and approval by CITY Purchasing and Contracts prior to the commencement of work by CONTRACTOR. Neither approval by CITY nor failure to disapprove the insurance furnished by CONTRACTOR shall relieve CONTRACTOR of CONTRACTOR’S full responsibility to provide the insurance required by this Contract. Compliance with the insurance requirements of this Contract shall not limit the liability of CONTRACTOR or its sub-contractors, employees or agents to CITY or others, and shall be in addition to and not in lieu of any other remedy available to CITY under this Contract or otherwise. CITY reserves the right to request and review a copy of any required insurance policy or endorsement to assure compliance with these requirements.

  • Regulatory Reports Flagstar and each of the Flagstar Subsidiaries have timely filed (or furnished, as applicable) all reports, forms, correspondence, registrations and statements, together with any amendments required to be made with respect thereto, that they were required to file (or furnish, as applicable) since January 1, 2018 with any Governmental Entity, including any report, form, correspondence, registration or statement required to be filed (or furnished, as applicable) pursuant to the laws, rules or regulations of the United States, any state, any foreign entity or any Governmental Entity, and have paid all fees and assessments due and payable in connection therewith, except where the failure to file (or furnish, as applicable) such report, form, correspondence, registration or statement or to pay such fees and assessments would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Flagstar. Subject to Section 9.15 and except for normal examinations conducted by a Governmental Entity in the ordinary course of business of Flagstar and the Flagstar Subsidiaries, no Governmental Entity has initiated or has pending any proceeding or, to the knowledge of Flagstar, investigation into the business or operations of Flagstar or any of the Flagstar Subsidiaries since January 1, 2018, except where such proceedings or investigations would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Flagstar. Subject to Section 9.15, there (x) is no unresolved violation, criticism, or exception by any Governmental Entity with respect to any report or statement relating to any examinations or inspections of Flagstar or any of the Flagstar Subsidiaries, and (y) has been no formal or informal inquiries by, or disagreements or disputes with, any Governmental Entity with respect to the business, operations, policies or procedures of Flagstar or any of the Flagstar Subsidiaries since January 1, 2018, in each case, except as would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect on Flagstar.

  • Regulatory Filings and Approvals Copies of all necessary governmental and third party approvals, registrations, and filings in respect of the transactions contemplated by this Agreement;

  • FDA As to each product subject to the jurisdiction of the U.S. Food and Drug Administration (“FDA”) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (“FDCA”) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a “Pharmaceutical Product”), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company's knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii) withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials relating to, any Pharmaceutical Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv) enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.

  • Cooperation with Regulatory Authorities The parties to this Agreement each agree to cooperate in a reasonable manner with each other in the event that any of them should become involved in a legal, administrative, judicial or regulatory action, claim, or suit as a result of performing its obligations under this Agreement.

  • Requisite Regulatory Approvals All Consents required to be obtained from or made with any Governmental Authority in order to consummate the transactions contemplated by this Agreement shall have been obtained or made.

  • Other Regulatory Approvals Each party hereto shall cooperate and use its reasonable best efforts to promptly prepare and file all necessary documentation to effect all necessary applications, notices, petitions, filings and other documents, and use all reasonable efforts to obtain (and will cooperate with each other in obtaining) any consent, acquiescence, authorization, order or approval of, or any exemption or nonopposition by, any Governmental Entity required to be obtained or made by Parent or the Company or any of their respective Subsidiaries in connection with the Offer and the Merger or the taking of any other action contemplated by this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.